Daily Anesthesiology Research Analysis
Three impactful anesthesiology-related studies stood out today: a translational Kidney International study links propofol to mitochondrial vulnerability in the thick ascending limb, with human data associating higher intraoperative exposure to worse renal outcomes. A large randomized trial shows cipepofol reduces respiratory adverse events versus propofol in elderly gastroscopy. A rigorous negative RCT finds single-injection parasternal intercostal plane blocks with liposomal bupivacaine do not
Summary
Three impactful anesthesiology-related studies stood out today: a translational Kidney International study links propofol to mitochondrial vulnerability in the thick ascending limb, with human data associating higher intraoperative exposure to worse renal outcomes. A large randomized trial shows cipepofol reduces respiratory adverse events versus propofol in elderly gastroscopy. A rigorous negative RCT finds single-injection parasternal intercostal plane blocks with liposomal bupivacaine do not reduce opioid use after cardiac surgery.
Research Themes
- Renal mitochondrial vulnerability to anesthetics
- Peri-procedural sedation safety in older adults
- Regional anesthesia efficacy and the value of negative trials
Selected Articles
1. Integrated spatial and functional metabolic profiling identified the thick ascending limb as a mitochondrial vulnerability hub in acute kidney injury.
Using spatial and single-cell omics with isotope tracing, the study identifies the outer medullary thick ascending limb as a metabolically active and injury-prone segment relying on oxidative phosphorylation and fatty acid oxidation. Propofol impaired oxidative phosphorylation in the outer medulla, worsened tubular injury in murine ischemia-reperfusion, and higher intraoperative exposure in transplant recipients correlated with reduced oxidative metabolism, greater tubular injury, and poorer long-term kidney outcomes.
Impact: This work connects mechanistic mitochondrial vulnerability to a widely used anesthetic and links exposure to clinical kidney outcomes, potentially reshaping sedative strategies in high-risk patients.
Clinical Implications: For patients at high risk of AKI (e.g., transplant recipients, ischemia-prone kidneys), consider minimizing propofol exposure, monitoring renal risk, and evaluating alternative sedatives to reduce mitochondrial stress in the outer medulla.
Key Findings
- The outer medullary thick ascending limb is a metabolic hotspot relying on oxidative phosphorylation and fatty acid oxidation, rendering it injury-prone.
- Propofol impaired oxidative phosphorylation in the outer medulla and shifted metabolism toward anaerobic glycolysis; in mice, preconditioning exacerbated tubular injury.
- In kidney transplant recipients, higher intraoperative propofol exposure was associated with reduced oxidative metabolism, increased tubular injury, and poorer long-term kidney outcomes.
Methodological Strengths
- Integrated multi-platform approach (spatial and single-cell transcriptomics, immunofluorescence, isotope tracing) across murine and human tissues.
- Translational linkage of mechanistic findings to human intraoperative exposure and clinical outcomes.
Limitations
- Human findings are observational and susceptible to confounding in exposure-outcome associations.
- Exact sample sizes and exposure quantification details for human cohorts are not provided in the abstract, limiting appraisal of effect size and generalizability.
Future Directions: Prospective studies to quantify dose–response of propofol exposure with renal metabolic injury, trials comparing alternative sedatives in high-risk AKI populations, and development of perioperative metabolic monitoring to personalize sedation.
INTRODUCTION: Acute kidney injury (AKI) is a common complication in critically ill patients and often progresses to chronic kidney disease (CKD), increasing morbidity and mortality. Despite its clinical relevance, the metabolic mechanisms underlying kidney injury remain poorly understood. METHODS: To help define this, we used an integrated approach combining spatial and single-cell transcriptomics, immunofluorescence, and isotope tracing imaging to investigate the spatial distribution of kidney energy metabolism in murine models and in human kidney allografts following transplantation. RESULTS: The
2. Respiratory-related safety profiles of ciprofol (cipepofol) for anesthesia/sedation in Chinese elderly patients undergoing gastroscopy: a multicenter, parallel controlled clinical trial (REST trial).
In 871 elderly patients undergoing gastroscopy, randomized to cipepofol or propofol, cipepofol significantly reduced respiratory-related adverse events and injection pain while maintaining 100% procedural success. Propofol had shorter procedure-related durations, but overall safety favored cipepofol.
Impact: Large randomized evidence supports an alternative sedative with fewer respiratory complications in a high-risk elderly population, directly informing endoscopy sedation protocols.
Clinical Implications: Consider cipepofol as a first-line sedative alternative to propofol for elderly gastroscopy when respiratory risk mitigation is prioritized; balance against slightly longer procedure-related durations.
Key Findings
- Cipepofol reduced respiratory-related adverse events versus propofol (22.3% vs 33.9%, P<0.001 in FAS).
- Injection pain was markedly lower with cipepofol (2.6% vs 28.4%, P<0.001).
- Procedure and insertion success were 100% in both groups; propofol had shorter procedure-related durations.
Methodological Strengths
- Randomized, parallel-controlled, multicenter design with a large elderly cohort.
- Predefined, clinically meaningful primary safety endpoint and multivariable adjustment.
Limitations
- Blinding is not specified; potential for performance bias.
- Procedure-related durations favored propofol, suggesting trade-offs not fully explored (e.g., workflow efficiency).
Future Directions: Head-to-head comparisons across endoscopic and non-endoscopic procedures, pharmacoeconomic analyses, and evaluation in patients with severe cardiopulmonary comorbidities.
BACKGROUND: A post-marketing, parallel-controlled clinical trial (REST trial) was conducted to evaluate the safety and efficacy of cipepofol versus propofol for the induction of anesthesia/sedation in Chinese elderly patients undergoing gastroscopy. METHODS: All enrolled patients aged ≥65 years were assigned randomly in a 1:1 ratio to be administered intravenous cipepofol-0.3 mg/kg or propofol-1.5 mg/kg. The primary endpoint was incidence of respiratory-related adverse events (AEs) including respiratory depression (respiratory rate < 8 breaths/min lasting for >30 s), apnea (loss of thoracic movement for >15 s) and hypoxemia (SpO RESULTS: Among 890 randomized patients, 871 were finally included in the full analysis set (FAS), with 431 receiving cipepofol and 440 receiving propofol. Patients treated with cipepofol had a significantly lower incidence of respiratory-related AEs compared to propofol treatment (FAS: 22.3 % vs. 33.9 %, per-protocol set: 20.6 % vs. 34.5 %, all P < 0.001), regardless of sex. Multivariable analysis revealed that the risk of patients experiencing respiratory-related AEs was 1.82 times higher in the propofol group compared to cipepofol group (P < 0.001). The success rates of the gastroscopy procedure and gastroscope insertion were both 100 % in the two groups. Gastroscopy procedure-related durations were shorter in propofol group compared to cipepofol group (all P < 0.05). Patients treated with cipepofol exhibited a significantly lower rate of treatment-emergent AEs (TEAEs) (55.0 % vs. 67.7 %, P < 0.001), TEAEs of special interest (53.4 % vs. 65.2 %, P < 0.001) and injection pain (2.6 % vs. 28.4 %, P < 0.001). CONCLUSIONS: Cipepofol-0.3 mg/kg is a safe and effective intravenous anesthetic for Chinese elderly patients undergoing gastroscopy, especially complimented by lower incidences of respiratory-related AEs and injection pain. CLINICAL TRIALS REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2100052299, registered on October 24, 2021.
3. Superficial parasternal intercostal plane blocks with liposomal bupivacaine did not significantly reduce opioid use after cardiac surgery: a randomized clinical trial.
In a double-blind RCT of 100 cardiac surgery patients, single-injection bilateral SPIP blocks with liposomal bupivacaine did not reduce 72-hour opioid consumption or improve pain and recovery metrics versus saline. The study suggests catheters or alternative techniques may be necessary to achieve clinically meaningful benefits.
Impact: A well-designed negative trial challenges assumptions about single-injection parasternal plane blocks with liposomal bupivacaine in sternotomy analgesia, guiding resource allocation and technique selection.
Clinical Implications: Avoid routine use of single-injection SPIP blocks with liposomal bupivacaine for sternotomy analgesia if the goal is opioid reduction; consider catheter techniques, multilevel injections, or targeting chest tube pain.
Key Findings
- No significant reduction in 72-hour opioid consumption with liposomal bupivacaine SPIP versus placebo (165 vs 205 MME; p=0.30).
- Secondary outcomes (pain scores, extubation time, ICU/hospital LOS, 90-day opioid use) were similar between groups.
- No serious adverse events occurred, supporting safety but limited efficacy of the single-injection approach.
Methodological Strengths
- Prospective, randomized, double-blind controlled design.
- Relevant, patient-centered outcomes including opioid use, pain, and recovery metrics with 90-day follow-up.
Limitations
- Single-injection technique may be insufficient; results may not generalize to catheter-based SPIP or multilevel approaches.
- Study powered for opioid consumption; may be underpowered for certain secondary outcomes.
Future Directions: Compare catheter-based SPIP, multilevel injections, alternative local anesthetics, and specific strategies for chest tube pain in adequately powered RCTs.
BACKGROUND: Acute pain after cardiac surgery via median sternotomy is commonly managed with multimodal analgesia, but optimal regional techniques remain uncertain. Superficial parasternal intercostal plane (SPIP) blocks have shown promise for postoperative pain control, with the use of catheters extending these benefits up to three days. This study evaluated the efficacy of single-injection SPIP blocks with liposomal bupivacaine in reducing opioid consumption following cardiac surgery. METHODS: In this prospective, randomized, double-blind controlled trial, 100 patients undergoing elective coronary artery bypass grafting or valve surgery via median sternotomy were randomized to receive bilateral SPIP blocks with either a mixture of bupivacaine and liposomal bupivacaine or saline placebo prior to incision. The primary outcome was total opioid consumption in oral morphine milligram equivalents (MME) over the first 72 postoperative hours. Secondary outcomes included pain scores, time to extubation, intensive care unit (ICU) and hospital length of stay and opioid use at 90 days. RESULTS: Total opioid consumption in the first 72 hours was not significantly different between groups (SPIP intervention: 165 (IQR 103-284) MME vs saline placebo: 205 (IQR 145-282) MME, p=0.30). Pain scores, extubation time, ICU and hospital length of stay, and opioid use at 90 days were also similar between groups. No serious adverse events were reported. CONCLUSIONS: Preincision bilateral SPIP blocks with a mixture of bupivacaine and liposomal bupivacaine did not significantly reduce opioid consumption or improve postoperative analgesic outcomes compared with saline placebo in cardiac surgical patients. These findings suggest that single-injection SPIP blocks with liposomal bupivacaine may not be as effective as repeated injections or catheters in cardiac surgical patients. Further studies should explore modifications to block techniques such as multilevel injections, the timing of the block relative to surgery, alternative local anesthetics, and strategies specifically targeting chest tube-related pain. TRIAL REGISTRATION NUMBER: NCT04928339.